Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Barbara Burtness MD
Barbara Burtness MD Advisory Board
Lee Schwartzberg MD, FACP
Lee S. Schwartzberg MD, FACP Advisory Board
Alexander van Akkooi MD, PhD, FRACS
Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor
See All Experts
Published in Oncology

Journal Scan / Research · October 28, 2024

Sequential 177Lu-PSMA-617 and Docetaxel vs Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Rodrigo Fonseca MD

The Lancet Oncology
Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study
Lancet Oncol 2024 Oct 01;25(10)1267-1276, AA Azad, M Bressel, H Tan, M Voskoboynik, A Suder, AJ Weickhardt, A Guminski, RJ Francis, J Saghebi, N Dhiantravan, AM Joshua, L Emmett, L Horvath, DG Murphy, E Hsiao, B Balakrishnar, P Lin, A Redfern, W Macdonald, S Ng, ST Lee, DA Pattison, D Nadebaum, ID Kirkwood, MS Hofman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated